Abstract
Calcium is the fifth most abundant inorganic element of the body, the principal component of the human skeleton, and a vital participant in normal neuromuscular function, blood coagulation, membrane function, and multiple enzyme reactions. Its transmembrane flux plays a critical role in hormone secretion and metabolic coordination. Exquisitely sensitive homeostatic mechanisms have evolved to monitor and regulate the calcium ion in plasma while allowing an enormous reservoir to exist in bone where it principally serves a mechanical function. The normal adult human has roughly 25 g of total body calcium per kg of lean body mass (about 1–1.5 kg). Ninety-nine percent of it is present in bone as calcium phosphate while only 1% of skeletal calcium is freely exchangeable with the extracellular fluid. Mobilization of extensive amounts of skeletal calcium requires active resorption such as that promoted by vitamin D and parathyroid hormone (PTH). Perhaps the most frequent challenge to calcium homeostasis occurs with dietary calcium deprivation. When this occurs, a triad of efficient systems join to combat any tendency to hypocalcemia (Figure 1). Hormonally-induced bone resorption probably represents the most important mechanism by which sudden deficits in calcium homeostasis are overcome. Reduction in urinary excretion of calcium and increased efficiency of calcium absorption from the gut (in response to calcium deficiency) serve as additional mechanisms for maintaining extracellular fluid calcium; the renal effect is probably more important than previously realized. Renal reabsorption of calcium can rise to essentially 100% but this occurs only if the calcium level drops below 7 mg/dl. If calcium is low but above this level, PTH seems to be the principal effector involved in renal calcium conservation (1–10).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bringhurst FR, Potts JT: Calcium and phosphate distribution, tumover, and metabolic actions. In: Endocrinology Vol II, DeGroot U (ed) New York, Grune & Stratton, 1979, p 551.
Glimcher MJ: Composition, structure and organization of bone and other mineralized tissues and the mechanism of calcification. In: Handbook of Physiology, Sec. 7: Endocrinology, Vol III, Aurbach GD (ed). Washington American Physiological Society, 1976, p25.
Sledge CB: Formation and resorption of bone. In: Textbook of Rheumatology, Kelley WN (ed). Philadelphia, Saunders, 1981, p277.
Parfitt AM, Kleerekoper M: Clinical disorders of calcium, phosphorus and magnesium metabolism. In: Clinical Disorders of Fluid and Electrolyte Metabolism, Maxwell MH, Kleeman CR (eds). New York, McGraw Hill, 1980, p947.
Rasmussen H, Bordier P: The Physiologic and Cellular Basis of Metabolic Bone Disease, Baltimore. Williams & Wilkins, 1974.
Borle AB: Parathyroid hormone and cell calcium. In: Calcium, Parathyroid Hormone, and Calcitonins, Talmage RV, Munson PL (eds). Amsterdam, Excerpta Medica, 1972.
Habner JF, Potts JT: Biosynthesis of parathyroid hormone. N Eng J Med 299: 580 - 635, 1978.
Coop DH: Parathyroids, calcitonin and control of calcium. Recent Prog Horm Res 20: 59, 1964.
Segre GV, d’Amour P, Rosenblatt M, Potts JT: Heterogeneity and metabolism of parathyroid hormone. In: Endocrinology of Calcium Metabolism, Copp DH, Talmage RV (eds). Amsterdam, Excerpta Medica, 1978.
Habener JF, Potts JT: Parathyroid physiology and primary hyperparathyroidism. In: Metabolic Bone Disease, Avioli LV, Krane SM (eds). New York Academic Press, Vol II 1978, pi.
Wilkinson R: Absorption of calcium, phosphorus, and magnesium. In: Calcium, Phosphate, and Magnesium Metabolism. Nordin BEC (ed), London, churchill Livingstone, 1976.
Holick MF: The cutaneous photosynthesis of previtamin D: a unique photoendocrine system. J Inv Dermatol 76: 51, 1981.
Haussler Mr, McCain BS: Basic and clinical concepts related to vitamin D metabolism and action. N Eng J Med 38. 297: 974, 1977.
Hughes MR, Baylink DJ, Jones PG, Haussler MR: Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 39. 1,25-(OH)2D3: Application to hypervitaminosis D. J Clinical Investigation 58: 61, 1976.
Bell NH: Hypercalcemic and hypocalcemic disorders: Diagnosis and treatment. Nephron 23: 147, 1979.
Jaun D: Hypocalcemia: Diffemtial diagnosis and mechansims. Arch Intern Med 139: 1166, 1979.
Paterson CR: Hypocalcemia: Differential diagnosis and investigation. Ann Clin Biochem 13: 578, 1976.
Slatopolsky E, Rosenbaum R, Mennes P, Klahr S: The hypocalcemia of magnesium depletion. Adv Exp Med Biol 103: 263, 1978.
Rastogi S, Arruda JAL: Hypocalcemia: Its clinical manifestations point to the diagnosis. Consultant July, 1983.
Mosekilde L, Melson F, Bagger JP, Sorenson NS: Bone changes in hyperthyroidism. Acta Endocrinol 85: 515, 1977.
Mosekilde L, Christensen MS: Decreased parathyroid function in hyperthyroidism. Acta Endocrinol 84: 566, 1977.
Kaptein EM, Singer FR, Nicoloff JT, Bishop JE, Norman AW: Plasma 1,25-dihydroxy vitamin D is decreased in hyperthyroidism. Clin Res 27: 369A, 1979.
Michie W, Duncan T: Mechanisms of hypocalcemia after thyroidectomy for thyrotoxicosis. Lancet 1: 508, 1971.
Nagant deDeuxchasisnes C: Dissociation of parathyroid hormone bioactivity and immunoreactivity in pseudohypoparathyroidism type 1. J Clin Endocrinol Metab 53: 1105, 1981.
Farfel Z: Defect of receptor-cyclase coupling protein in pseudo hypoparathyroidism. N Eng J Med 303: 237, 1980.
Nordin BEC, Peacock M: Role of the kidney in regulation 50. of plasma calcium. Lancet 2: 1280, 1969.
Porter RH, Cox BG, Heaney D, Hostetter TH, Stinebaugh BJ, Suki WN: Treatment of hypoparathyroid patients with 51. chlorthalidone. N Eng J Med 298: 577, 1978.
Nagant de Dewxchaisnes C: Hyperparathyroidism. In: Metabolic Bone Disease. Vol 2, Avioli LV, Krane SM (eds). New York, Academic Press, 1978.
Myers WPL: Hypercalcemia associated with malignant disease. In: Endocrine and Nonendocrine Hormone-Producing Tumors. Chicago: Year Book Medical, 1973, p 147.
Gottlieb S, Rude RK, Sharp CF, Singer FR: Humoral hypercalcemia of malignancy: a syndrome in search of a hormone. Am J Med 73: 751, 1982.
Heath H: Primary hyperparathyroidism: Incidence, morbidity, and potential economic impact in a commimity. N Eng J Med 302: 189, 1980.
Castleman B, Schantz A, Roth SL: Parathyroid hyperplasia in primary hyperparathyroidism — A review of 85 cases. Cancer 38: 1668, 1976.
Schantz A, Castleman B: Parathyroid carcinoma — A study of 70 cases. Cancer 31: 600, 1973.
Baxter JD, Bondy PK: Hypercalcemia of thyrotoxicosis. Ann Internal Med 65: 429, 1966.
Parfitt AM, Dent CE: Hyperthyroidism and hypercalcemia. Q J Med 39: 171, 1970.
Adams PH, Jowsey J, Kelly PJ, et al: Effects of hyperthyroidism on bone and mineral metabolism in man. QJ Med 36: 1, 1976.
Shetty KR, Ajlouni K, Rosenfeld PS. Protracted vitamin D intoxication. Arch Internal Med 135: 986, 1975.
Barbour GL. Hypercalcemia in an anephric patient with sarcoidosis. Evidence for extrarenal generation of 1,25 di- hydroxyvitamin D. N Eng J Med 305: 440, 1981.
Suki WN, Hull AR, Rector FC, et al: Mechanism of the effect of thiazide diuretics on calcium and uric acid. Clin Research 15: 78, 1967.
Brinkman AS, Massry SG, Cobum JW. Changes in serum and urinary calcium during treatment with hydorchlorthiazide. J ain Invest 51: 945, 1972.
McMillian DE, Freeman RB: The milk alkali syndrome: A study of the acute disorder with comments of the development of the chronic condition. (Medicine 44: 485, 1965.
Pederson KO: Hypercalcemia in Addisons disease. Acta Med Scand 181: 691, 1967.
Frame B, Jackson CE, Reynolds WA, Unphrey JE: Hypercalcemia and skeletal effects of chronic hypervitaminosis A. Ann Internal Med 80: 44, 1974.
Raisz LH: Comparison of commercially available parathyroid hormone immunoassays in differential diagnosis of hypercalcemia due to primary hyperparathyroidism of malignancy. Ann Int Med 91: 739, 1979.
Stewart AF: Biochemical evaluation of patients with cancer-associated hypercalcemia. N Eng J Med 303: 1377, 1980.
Deftos U, Nees RM: Medical management of the hypercalcemia of malignancy. Ann Rev Med 25: 323, 1974.
Suki Wn, Yium JJ, VonMinden M, Eknoyan G, Martinez- Maldonado M: Acute treatment of hypercalcemia with furosemide. N Eng J Med 283: 836, 1970.
Rodman JS, Sherwood LM: Disorders of mineral metabolism. In: Metabolic Bone Disease, Vol 2, Avioli LV, Krane S, (eds). New York, Academic Press, 1978, p578,.
Strauck BS, Ball MF: Hemodialysis in the treatment of severe hypercalcemia. JAMA 235: 1347, 1976.
Nolph KD, Stoh M, Maher JF: Calcium free peritoneal dialysis. Treatment of vitamin D intoxication. Arch Int Med 128: 809, 1971.
Stolz ML, Nolph KD, Maher JF: Factors affecting calcium removal with calcium-free peritoneal dialysis. J Lab Clin Med 78: 389, 1971.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishing, Boston/ The Hague/ Dordrecht/ Lancaster
About this chapter
Cite this chapter
Hughes, M.R., Suki, W.N. (1984). Hypocalcemia and Hypercalcemia. In: Suki, W.N., Massry, S.G. (eds) Therapy of Renal Diseases and Related Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3807-9_6
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3807-9_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3809-3
Online ISBN: 978-1-4613-3807-9
eBook Packages: Springer Book Archive